Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 28, 2013, Pages 11565-11570

  Stanley, Sarah A ^a,b,c   Kawate, Tomohiko ^a,b,c   Iwase, Noriaki ^a,b,c   Shimizu, Motohisa ^a,b,c   Clatworthy, Anne E ^a,b,c   Kazyanskaya, Edward ^a   Sacchettini, James C ^d   Ioerger, Thomas R ^e   Siddiqi, Noman A ^f   Minami, Shoko ^f   Aquadro, John A ^a   Grant, Sarah Schmidt ^a,b,c   Rubin, Eric J ^f   Hung, Deborah T ^a,b,c  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Department of Biochemistry and Biophysics ^*  (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIARYL 5,7 DIMETHYL COUMARIN DERIVATIVE; CARRIER PROTEIN; CCA 34; COUMARIN DERIVATIVE; FATTY ACID DEGRADATION PROTEIN D32; ISONIAZID; MYCOLIC ACID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL WALL; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOGENESIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BACTERIAL PROTEINS; COUMARINS; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; ZEBRAFISH;

ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84879939125     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1302114110     Document Type: Article

References (42)

1. Dye C (2006) Global epidemiology of tuberculosis. Lancet 367(9514):938-940.
2. Makarov V, et al. (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928):801-804.
3. Stover CK, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405(6789):962-966. (Pubitemid 30435054)
4. Andries K, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223-227. (Pubitemid 40116230)
5. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48(1):77-84. (Pubitemid 36411469)
6. Sassetti CM, Rubin EJ (2003) Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA 100(22):12989-12994. (Pubitemid 37340013)
7. Sacchettini JC, Rubin EJ, Freundlich JS (2008) Drugs versus bugs: In pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 6(1):41-52. (Pubitemid 350286219)
8. Lee M, et al. (2012) Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367(16):1508-1518.
9. Singh R, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322(5906):1392-1395. (Pubitemid 352775253)
10. Krieger IV, et al. (2012) Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem Biol 19(12):1556-1567.
11. Banerjee A, et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263(5144):227-230. (Pubitemid 24067929)
12. Vilchèze C, et al. (2011) Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother 55(8):3889-3898.
13. Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C (2010) A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem 285(19):14330-14337.
14. Boyne ME, et al. (2007) Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: Evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob Agents Chemother 51(10):3562-3567. (Pubitemid 47519344)
15. Collins LA, Torrero MN, Franzblau SG (1998) Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42(2):344-347. (Pubitemid 28114442)
16. Stanley SA, et al. (2012) Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7(8):1377-1384.
17. Jia C, et al. (2000) Efficient activation of aromatic C-H bonds for addition to C-C multiple bonds. Science 287(5460):1992-1995. (Pubitemid 30158669)
18. Jia C, Piao D, Kitamura T, Fujiwara Y (2000) New method for preparation of coumarins and quinolinones via Pd-catalyzed intramolecular hydroarylation of C-C triple bonds. J Org Chem 65(22):7516-7522.
19. Li K, Zeng Y, Neuenswander B, Tunge JA (2005) Sequential Pd(II)-Pd(0) catalysis for the rapid synthesis of coumarins. J Org Chem 70(16):6515-6518. (Pubitemid 41076542)
20. Pethe K, et al. (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57.
21. Gomez JE, McKinney JD (2004) M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84(1-2):29-44. (Pubitemid 38082931)
22. Xie Z, Siddiqi N, Rubin EJ (2005) Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 49(11):4778-4780. (Pubitemid 41552617)
23. Ioerger TR, et al. (2010) The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 11:670.
24. Tandon R, et al. (2011) Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: Structure-activity relationships. J Antimicrob Chemother 66(11):2543-2555.
25. Virsdoia V, et al. (2010) Screening for in vitro antimycobacterial activity and three-dimensional quantitative structure-activity relationship (3D-QSAR) study of 4-(arylamino)coumarin derivatives. Chem Biol Drug Des 76(5):412-424.
26. Ananthan S, et al. (2009) High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89(5):334-353.
27. Portevin D, et al. (2005) The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: Identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J Biol Chem 280(10):8862-8874. (Pubitemid 40409576)
28. Carroll P, Faray-Kele M-C, Parish T (2011) Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl Environ Microbiol 77(14):5040-5043.
29. Takayama K, Wang C, Besra GS (2005) Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev 18(1):81-101. (Pubitemid 40170662)
30. Trivedi OA, et al. (2004) Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature 428(6981):441-445. (Pubitemid 38419691)
31. Léger M, et al. (2009) The dual function of the Mycobacterium tuberculosis FadD32 required for mycolic acid biosynthesis. Chem Biol 16(5):510-519.
32. Boshoff HIM, et al. (2004) The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action. J Biol Chem 279(38):40174-40184. (Pubitemid 39258293)
33. Lesley R, Ramakrishnan L (2008) Insights into early mycobacterial pathogenesis from the zebrafish. Curr Opin Microbiol 11(3):277-283.
34. Adams KN, et al. (2011) Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145(1):39-53.
35. Arora P, et al. (2009) Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis. Nat Chem Biol 5(3):166-173.
36. Galandrin S et al. (2013) Assay development for identifying inhibitors of the mycobacterial FadD32 activity. J Biomol Screen 18(5):576-587.
37. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6(1):29-40. (Pubitemid 46020284)
38. Young DB, Perkins MD, Duncan K, Barry CE, 3rd (2008) Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 118(4):1255-1265. (Pubitemid 351500418)
39. Jindani A, Doré CJ, Mitchison DA (2003) Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167(10):1348-1354. (Pubitemid 36609718)
40. Thompson N; International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 60(4):555-564.
41. Ehrt S, et al. (2005) Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33(2):e21.
42. Clatworthy AE, et al. (2009) Pseudomonas aeruginosa infection of zebrafish involves both host and pathogen determinants. Infect Immun 77(4):1293-1303.